Skip to main content
. 2019 Sep;11(9):3980–3990. doi: 10.21037/jtd.2019.08.92

Table 2. The relationships between AFU levels and baseline characteristics in patients with stage T1N0 ESCC.

Characteristic AFU ≤17.95 (n=52) AFU >17.95 (n=108) P*
Gender 0.900
   Male 39 80
   Female 13 28
Age (years) 0.069
   <65 29 76
   ≥65 23 32
Smoking history 0.019
   Yes 21 65
   No 31 43
Alcohol consumption 0.123
   Yes 4 18
   No 48 90
Performance status 0.115
   0 45 99
   1 5 9
   2 2 0
Differentiation 0.582
   Well 10 14
   Moderate 26 58
   Poor 16 36
Tumor location 0.932
   Upper 9 17
   Middle 34 70
   Lower 9 21
Length of tumor, cm 0.893
   ≤1.8 14 28
   <1.8 38 80
Surgical approach 0.958
   Sweet 33 69
   McKeown 19 39
Reconstructed organ
   Gastric tube 52 107
Anastomosis 0.759
   Hand-sewn 5 12
   Stapled 47 95
Depth of tumor invasion 0.065
   T1a 17 21
   T1b 35 87
Adjuvant therapy 0.965
   Yes 2 4
   No 50 104
Resected lymph nodes count (mean ± SD) 19.4±11.2 20.1±12.1 0.676
Resected lymph nodes stations (mean ± SD) 6.48±3.50 6.11±3.36 0.644
ALT 0.012
   ≤18.55 36 52
   >18.55 16 56
AST 0.581
   ≤15.35 10 17
   >15.35 42 91
ALT/AST 0.063
   ≤0.75 21 28
   >0.75 31 80
GGT 0.005
   ≤21.85 35 47
   >21.85 17 61
LDH 0.971
   ≤170.20 35 73
   >170.20 17 35

*, P value less than 0.05 indicated a statistically significant difference. ESCC, esophageal squamous cell carcinoma; OS, overall survival; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase; LDH, lactate dehydrogenase; AFU, alpha-l-fucosidase.